HK1205683A1 - Pharmaceutical formulation having improved stability - Google Patents
Pharmaceutical formulation having improved stabilityInfo
- Publication number
- HK1205683A1 HK1205683A1 HK15106214.0A HK15106214A HK1205683A1 HK 1205683 A1 HK1205683 A1 HK 1205683A1 HK 15106214 A HK15106214 A HK 15106214A HK 1205683 A1 HK1205683 A1 HK 1205683A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pharmaceutical formulation
- improved stability
- stability
- improved
- formulation
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/HU2012/000013 WO2013121233A1 (en) | 2012-02-17 | 2012-02-17 | Pharmaceutical formulation having improved stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1205683A1 true HK1205683A1 (en) | 2015-12-24 |
Family
ID=45922707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15106214.0A HK1205683A1 (en) | 2012-02-17 | 2015-06-30 | Pharmaceutical formulation having improved stability |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150094345A1 (de) |
| EP (2) | EP2814465B1 (de) |
| CN (2) | CN104254321A (de) |
| AU (2) | AU2012369903A1 (de) |
| BR (1) | BR112014020184B1 (de) |
| CA (1) | CA2864456A1 (de) |
| EA (1) | EA030466B1 (de) |
| HK (1) | HK1205683A1 (de) |
| HU (1) | HUE046229T2 (de) |
| IL (1) | IL233972A0 (de) |
| MX (1) | MX370647B (de) |
| PH (1) | PH12014501840A1 (de) |
| PL (1) | PL2814465T3 (de) |
| UA (1) | UA113977C2 (de) |
| WO (1) | WO2013121233A1 (de) |
| ZA (1) | ZA201405925B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012011118A2 (en) * | 2010-05-13 | 2012-01-26 | Purshotama Sagi Reddy Babu Reddy | Development of a fixed dose combination dosage form containing ramipril and carvedilol |
| EP2814465B1 (de) | 2012-02-17 | 2019-07-03 | Egis Gyógyszergyár Zrt. | Pharmazeutische formulierung mit erhöhter stabilität |
| HUP1300496A2 (hu) | 2013-08-16 | 2015-03-02 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Stabil kombinációs gyógyszerkészítmény |
| WO2020109319A1 (en) | 2018-11-27 | 2020-06-04 | Zaklady Farmaceutyczne Polpharma S.A | Pharmaceutical composition comprising ramipril and indapamide |
| CN114748436B (zh) * | 2022-05-30 | 2023-05-16 | 迪沙药业集团有限公司 | 一种硝苯地平组合物及其制备方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE20469T1 (de) | 1980-10-23 | 1986-07-15 | Schering Corp | Carboxyalkyl-dipeptide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel. |
| DE3226768A1 (de) | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
| DE3739690A1 (de) | 1987-11-24 | 1989-06-08 | Hoechst Ag | Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen |
| FR2824477B1 (fr) * | 2001-05-09 | 2005-09-09 | Ethypharm Lab Prod Ethiques | Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes |
| HU226642B1 (en) | 2001-12-17 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Amlodipine bezylate tablets having extended stability and process for producing the same |
| US20030215526A1 (en) | 2002-03-08 | 2003-11-20 | Scott Stofik | Stable formulations of angiotensin converting enzyme (ACE) inhibitors |
| DE602004019777D1 (de) | 2003-06-26 | 2009-04-16 | Teva Pharma | STABILE PHARMAZEUTISCHE ZUBEREITUNGEN MIT 2-AZA-BICYCLOi3.3.0 -OCTAN-3-CARBOXYLSÄURE-DERIVATEN |
| EP1694308A1 (de) | 2003-10-30 | 2006-08-30 | Lupin Ltd. | Stabile formulierungen von ace-hemmern und herstellungsverfahren dafür |
| GB2394660A (en) | 2003-12-17 | 2004-05-05 | Niche Generics Ltd | Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide |
| EA011862B1 (ru) | 2004-03-24 | 2009-06-30 | Актавис Груп Хф. | Композиции рамиприла |
| KR20070085754A (ko) * | 2004-11-05 | 2007-08-27 | 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 | 안정화된 라미프릴 조성물 및 제조 방법 |
| CN100374462C (zh) | 2005-11-21 | 2008-03-12 | 大连帝恩生物工程有限公司 | 截短胰高血糖素样肽1(sGLP-1)、制法及其应用 |
| US20070232680A1 (en) * | 2006-04-04 | 2007-10-04 | Vijayabhaskar Bolugoddu | Preparation of ramipril and stable pharmaceutical compositions |
| CN101489550A (zh) * | 2006-04-19 | 2009-07-22 | 特瓦制药工业有限公司 | 2-氮杂-二环[3.3.0]-辛烷-3-羧酸衍生物的稳定药物组合物 |
| EP1901739A2 (de) * | 2006-04-19 | 2008-03-26 | Teva Pharmaceutical Industries Ltd | Stabile pharmazeutische zusammensetzungen aus 2-aza-bicyclo[3.3.0]-octan-3-carboxylsäure-derivaten |
| US20070281000A1 (en) * | 2006-06-02 | 2007-12-06 | Michael Fox | Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof |
| BRPI0621739A2 (pt) * | 2006-06-02 | 2011-12-20 | Teva Pharma | formulação estável que consiste em drogas sensìveis à umectação e seu procedimento de fabricação |
| EP2034966A1 (de) | 2006-06-30 | 2009-03-18 | Alphapharm Pty Ltd. | Stabilisierte zusammensetzung mit ace-hemmern |
| EP2049089A4 (de) | 2006-08-08 | 2012-07-04 | Accu Break Technologies Inc | Pharmazeutische tabletten mit mehreren wirkstoffsegmenten |
| WO2008065485A2 (en) | 2006-10-19 | 2008-06-05 | Torrent Pharmaceuticals Limited | Stable pharmaceutical compositions of a calcium channel blocker and an ace inhibitor |
| GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
| WO2008068217A2 (en) * | 2006-12-04 | 2008-06-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system |
| CA2677623C (en) | 2007-02-09 | 2015-04-07 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
| WO2008132756A1 (en) | 2007-05-01 | 2008-11-06 | Lupin Limited | Stable pharmaceutical compositions of ramipril |
| HU230877B1 (hu) | 2008-09-30 | 2018-11-29 | EGIS Gyógyszergyár NyR | Stabil kombinációs gyógyszerkészítmény |
| PE20130004A1 (es) * | 2010-02-24 | 2013-02-01 | Sanofi Aventis Deutschland | Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion |
| EP2814465B1 (de) | 2012-02-17 | 2019-07-03 | Egis Gyógyszergyár Zrt. | Pharmazeutische formulierung mit erhöhter stabilität |
-
2012
- 2012-02-17 EP EP12711438.7A patent/EP2814465B1/de active Active
- 2012-02-17 PL PL12711438T patent/PL2814465T3/pl unknown
- 2012-02-17 CN CN201280069949.6A patent/CN104254321A/zh active Pending
- 2012-02-17 US US14/379,382 patent/US20150094345A1/en not_active Abandoned
- 2012-02-17 UA UAA201410026A patent/UA113977C2/uk unknown
- 2012-02-17 EP EP18209851.7A patent/EP3501501A1/de not_active Withdrawn
- 2012-02-17 EA EA201491510A patent/EA030466B1/ru not_active IP Right Cessation
- 2012-02-17 MX MX2014009871A patent/MX370647B/es active IP Right Grant
- 2012-02-17 CN CN201710824593.7A patent/CN107441495A/zh active Pending
- 2012-02-17 BR BR112014020184-6A patent/BR112014020184B1/pt active IP Right Grant
- 2012-02-17 WO PCT/HU2012/000013 patent/WO2013121233A1/en active Application Filing
- 2012-02-17 AU AU2012369903A patent/AU2012369903A1/en not_active Abandoned
- 2012-02-17 CA CA2864456A patent/CA2864456A1/en not_active Abandoned
- 2012-02-17 HU HUE12711438A patent/HUE046229T2/hu unknown
-
2014
- 2014-08-06 IL IL233972A patent/IL233972A0/en unknown
- 2014-08-13 ZA ZA2014/05925A patent/ZA201405925B/en unknown
- 2014-08-14 PH PH12014501840A patent/PH12014501840A1/en unknown
-
2015
- 2015-06-30 HK HK15106214.0A patent/HK1205683A1/xx unknown
-
2016
- 2016-05-26 AU AU2016203463A patent/AU2016203463A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA030466B1 (ru) | 2018-08-31 |
| IL233972A0 (en) | 2014-09-30 |
| CA2864456A1 (en) | 2013-08-22 |
| UA113977C2 (xx) | 2017-04-10 |
| PL2814465T3 (pl) | 2020-01-31 |
| US20150094345A1 (en) | 2015-04-02 |
| AU2012369903A1 (en) | 2014-09-04 |
| EP3501501A1 (de) | 2019-06-26 |
| CN107441495A (zh) | 2017-12-08 |
| MX370647B (es) | 2019-12-19 |
| MX2014009871A (es) | 2015-03-19 |
| EP2814465B1 (de) | 2019-07-03 |
| PH12014501840A1 (en) | 2014-11-10 |
| ZA201405925B (en) | 2015-11-25 |
| EP2814465A1 (de) | 2014-12-24 |
| HUE046229T2 (hu) | 2020-02-28 |
| AU2016203463A1 (en) | 2016-07-07 |
| CN104254321A (zh) | 2014-12-31 |
| BR112014020184A2 (de) | 2017-06-20 |
| BR112014020184B1 (pt) | 2021-11-30 |
| BR112014020184A8 (pt) | 2017-07-11 |
| EA201491510A1 (ru) | 2014-11-28 |
| WO2013121233A1 (en) | 2013-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1211209A1 (en) | Pharmaceutical formulation containing thienotriazolodiazepine compounds | |
| HK1209638A1 (en) | Pharmaceutical compositions | |
| HK1203812A1 (en) | Novel pharmaceutical formulations | |
| ZA201501930B (en) | Pharmaceutical composition | |
| HK1210033A1 (en) | Pharmaceutical compositions having improved storage stability | |
| EP2832730A4 (de) | Mirabegronhaltige pharmazeutische zusammensetzung | |
| HK1205146A1 (en) | Pharmaceutical formulation | |
| AP3803A (en) | Pharmaceutical dosage form | |
| ZA201306000B (en) | Stable formulation | |
| GB201205164D0 (en) | Pharmaceutical compounds | |
| AP2015008208A0 (en) | Pharmaceutical administration forms comprising | |
| HK1205683A1 (en) | Pharmaceutical formulation having improved stability | |
| LT2934544T (lt) | Farmacinė kompozicija, apimanti ciklezonidą | |
| ZA201502987B (en) | Pharmaceutical composition | |
| EP2934542A4 (de) | Pharmazeutische verbindungen | |
| EP2897590A4 (de) | Pharmazeutische zusammensetzung | |
| GB201211153D0 (en) | Pharmaceutical compositions | |
| GB201202027D0 (en) | Pharmaceutical compounds | |
| HK1209339A1 (en) | Pharmaceutical formulations | |
| HK1204945A1 (en) | Pharmaceutical formulation containing flupirtin | |
| EP2851078A4 (de) | Pharmazeutische zusammensetzung | |
| IL238075A0 (en) | pharmaceutical preparations | |
| ZA201502354B (en) | Pharmaceutical dosage form | |
| GB201211406D0 (en) | Pharmaceutical formulations | |
| GB201211403D0 (en) | Pharmaceutical formulations |